LFLinni Fan

Linni Fan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Linni Fan has a total of 96 co-authors. Here are the top co-authors by number of shared publications:

  • Jia Chai

    State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Pathology, School of Basic Medicine and Xijing Hospital, Fourth Military Medical University

    3 shared publications
  • Jing Ma

    Department of Pathology, State Key Laboratory of Cancer Biology, Xijing Hospital, Air Force Military Medical University

    3 shared publications
  • Yingmei Wang

    State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Pathology, School of Basic Medicine and Xijing Hospital, Fourth Military Medical University

    3 shared publications
  • Yixiong Liu

    State Key Laboratory of Cancer Biology, Department of Pathology, The First Affiliated Hospital of Air Force Military Medical University, Xi’an, China

    3 shared publications
  • Zhe Wang

    Department of Pathology, State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Xijing Hospital, School of Basic Medicine, Fourth Military Medical University, Xi’an, China

    3 shared publications
  • Zhiyong Yin

    Department of Cardiology, the First Affiliated Hospital of Air Force Military Medical University, Xi'an, China

    3 shared publications

Latest Publications

  • Open Access

    Research progress on the compositional characteristics of the tumor immune microenvironment and immunopredictive models in esophageal squamous cell carcinoma

    by Gongcheng Wang, Zhenzhen Li, Siyu Tan, Jing Ma, Zhiyong Yin, Juan Du, Linni Fan

    1. Surgery, radiation, chemotherapy, and targeted therapy are the standard treatments for ESCC.1 Survival prospects for individuals with advanced ESCC have improved dramatically as neoadjuvant immu...


  • Open Access

    Expression of ribosomal S6 kinase 4 in bladder cancer and its correlation with clinicopathological features

    by Zhenzhen Li, Gongchen Wang, Siyu Tan, Yingmei Wang, Junyi Feng, Chen Wei, Jia Chai, Yanru Yang, Zhiyong Yin, Xiaoyan Zhou, et al.

    Context: Bladder cancer management is challenged by limited therapeutic targets and heterogeneous treatment responses. Ribosomal S6 kinase 4 (RSK4) has been established as an oncogenic driver in several malignancies, although its clinical significance in bladder cancer remains undefined. Objective: To evaluate RSK4 protein expression in bladder cancer specimens and assess its association with clinicopathologic features and patient outcomes. Design: RSK4 expression was analyzed by immunohistochemistry in a retrospective cohort of 143 bladder cancer specimens, including 93 cases represented in a tissue microarray. Statistical analyses were performed to evaluate the associations between RSK4 expression levels, standard clinicopathological parameters, and overall survival. Results: RSK4 immunoreactivity was detected in 65.7% (94/143) of tumor tissue samples but in 36.5% (23/63) of matched normal urothelial tissue samples (P < 0.0001). Elevated RSK4 expression was significantly correlated with the following established markers of disease progression: muscularis propria invasion (P < 0.001), high tumor grade (P < 0.01), advanced TNM stage (P < 0.001), lymph node metastasis (P < 0.01), and distant metastasis (P < 0.05). No significant associations were observed with patient age, sex, or tumor size. Multivariate analysis confirmed RSK4 as an independent predictor of reduced overall survival (HR = 2.34, 95% CI 1.42–3.85, P < 0.001). Subcellular studies indicate that RSK4 overexpression enhances the invasive and metastatic capabilities of bladder cancer cell lines, and vice versa. Conclusions: This study elucidates the expression pattern and mechanism of action of RSK4 in bladder urothelial carcinoma, confirming that its overexpression is a key factor for predicting poor prognosis. This discovery highlights the potential value of RSK4 as a significant therapeutic target, providing a new theoretical basis for improving clinical outcomes in bladder cancer.

  • Added value of multiparametric MRI for diagnosing subcentimeter functional adrenal nodules in primary aldosteronism using CXCR4-targeted PET/MRI

    by Xiaoli Meng, Zhiyong Quan, Linni Fan, Mingru Zhang, Guiyu Li, Mengwei Xu, Jia Wang, Wenhui Ma, Weidong Yang, Bo Yang, et al.

    Objective This study aims to evaluate the clinical utility of 68Ga-pentixafor PET/MRI in diagnosing primary aldosteronism (PA) in functional adrenal nodules, with a particular focus on subcentimeter nodules. Additionally, the diagnostic performance of integrated PET/MRI is compared to single-modality PET imaging. Methods A total of 62 patients with clinical suspicion of PA were enrolled from a tertiary hospital in China. Prior to adrenalectomy, all patients underwent 68Ga-pentixafor PET/MRI, followed by CXCR4 and CYP11B2 immunohistochemical analysis post-surgery. Adrenal lesions were stratified into two size groups: ≥ 1 cm and < 1 cm. Quantitative PET parameters, including SUVmax, SUVmean, and lesion-to-liver uptake ratio (LLR), were evaluated alongside MRI parameters such as outphase/inphase signal ratio (OIR), relative percent washout (RPW), T2-weighted image intensity, apparent diffusion coefficient (ADC). Receiver operating characteristic (ROC) curve analysis was performed to establish diagnostic thresholds. Comparative analyses were conducted between single-modality PET and integrated PET/MRI for diagnostic accuracy. Results Among 62 patients, 74 adrenal lesions were confirmed pathologically, comprising 37 aldosterone-producing adenomas (APA, ≥ 1 cm), 21 aldosterone-producing micronodules (micro-APA, < 1 cm), and 16 non-functioning adenomas (NFA). Key PET/MRI parameters, including SUVmax, SUVmean, LLR, OIR, and RPW, showed significant differentiation between functional adrenal nodules and normal adrenal glands (P < 0.001). For nodules ≥ 1 cm, the PET SUVmax threshold of 7.87 achieved a sensitivity of 92.3% and specificity of 95.0% for APA diagnosis. For nodules < 1 cm, the PET SUVmax threshold of 6.49 yielded a sensitivity of 68.8% and specificity of 83.3% for micro-APA diagnosis. Integrated PET/MRI significantly improved the diagnostic sensitivity for PA subcentimeter nodules from 68.8% (with PET alone) to 87.5%, and increased the area under the ROC curve from 0.760 to 0.854, with no significant reduction in diagnostic specificity. Conclusion 68Ga-Pentixafor PET/MRI demonstrated high diagnostic accuracy for functional adrenal nodules in PA, particularly enhanced sensitivity for subcentimeter nodules compared to PET alone.


  • Open Access

    RSK4 promotes the metastasis of clear cell renal cell carcinoma by activating RUNX1-mediated angiogenesis

    by Jing Ma, Yanru Yang, Kaijing Wang, Jin Liu, Junyi Feng, Gongcheng Wang, Shuangping Guo, Linni Fan

    Ribosomal S6 protein kinase 4 (RSK4), a member of the serine‒threonine kinase family, plays a vital role in the Ras‒MAPK pathway. This kinase is responsible for managing several cellular activities, including cell growth, proliferation, survival, and mobility. In this study, we observed higher RSK4 protein expression in clear cell renal cell carcinoma (ccRCC) than in normal kidney tissue, and the overexpression of RSK4 might predict poor outcomes for ccRCC patients. Notably, renal cell carcinoma (RCC) is rich in blood vessels; therefore, this study aimed to explore the biological function of RSK4 in ccRCC progression and its specific regulatory mechanism. We analyzed changes in the expression of target genes through transcriptomic and proteomic assessments. We also conducted tube formation assays and VEGF ELISAs to understand the role of RSK4 in angiogenesis. Additionally, we evaluated the regulatory effect of RUNX1 on EPHA2 transcription using a luciferase reporter gene assay and observed that the effect of RUNX1 on activating EPHA2 transcription was negated after the binding site was mutated. Our findings suggested that RSK4 enhanced tube formation by stimulating VEGF secretion. Concurrently, in vivo experiments confirmed that RSK4 expedited RCC metastasis and angiogenesis. This evidence indicates that RSK4 may serve as a new prognostic marker and play a vital role in RCC metastasis.


  • Top Cited Papers

    Cysteine carboxyethylation generates neoantigens to induce HLA-restricted autoimmunity

    by Yue Zhai, Liang Chen, Qian Zhao, Zhao-Hui Zheng, Zhi-Nan Chen, Huijie Bian, Xu Yang, Huan-Yu Lu, Peng Lin, Xi Chen, et al.

    Autoimmune diseases such as ankylosing spondylitis (AS) can be driven by emerging neoantigens that disrupt immune tolerance. Here, we developed a workflow to profile posttranslational modifications involved in neoantigen formation. Using mass spectrometry, we identified a panel of cysteine residues differentially modified by carboxyethylation that required 3-hydroxypropionic acid to generate neoantigens in patients with AS. The lysosomal degradation of integrin αIIb [ITGA2B (CD41)] carboxyethylated at Cys96 (ITGA2B-ceC96) generated carboxyethylated peptides that were presented by HLA-DRB1*04 to stimulate CD4 + T cell responses and induce autoantibody production. Immunization of HLA-DR4 transgenic mice with the ITGA2B-ceC96 peptide promoted colitis and vertebral bone erosion. Thus, metabolite-induced cysteine carboxyethylation can give rise to pathogenic neoantigens that lead to autoreactive CD4 + T cell responses and autoantibody production in autoimmune diseases.


  • Open Access

    Low expression of H3K27me3 is associated with poor prognosis in conventional chordoma

    by Jie Wei, Jianfeng Wu, Zhiyong Yin, Xia Li, Yixiong Liu, Yingmei Wang, Zhe Wang, Chao Xu, Linni Fan

    Purpose: Chordoma is a rare and locally invasive neoplasm, and the prognostic factors are limited. Deregulation of Histone 3 lysine 27 (H3K27) trimethylation (H3K27me3) is considered to be related with poor prognosis in some tumors. The purpose of this study was to detect the expression of H3K27me3 in chordomas and analyze the correlation with clinicopathological features and explore the roles as potential prognostic markers and therapeutic targets.Material and method: Specimens of 162 chordoma patients (consisting of 156 conventional chordoma, 4 dedifferentiated chordoma and 2 poorly differentiated chordoma) were enrolled in a tissue microarray (TMA) in order to assess the immunohistochemical staining by H3K27me3 antibodies. Correlations between H3K27me3 expression and clinicopathological features were analyzed. Clinical data of the patients were correlated and survival analysis was performed. Kaplan-Meier survival curves and log-rank test were used to analyze the recurrence-free survival (RFS) and overall survival (OS). Multivariate Cox regression analyses were used to identify potential prognostic factors.Results: The expression of H3K27me3 was lower in 37 chordoma patients (37/162, 22.8%), and higher in 125 patients (125/162, 77.2%). H3K27me3-low expression significantly correlated with spine location (P < 0.001), conventional histological subtype (P < 0.001), and recurrence (P < 0.001). Log-rank test showed that H3K27me3-low expression was associated with poor RFS (P =0.027) and OS (P =0.009) in conventional chordoma patients. Cox multivariate analysis revealed that low expression of H3K27me3 was an independent predictor of poor OS (P =0.007) and RFS (P =0.025) in conventional chordoma patients.Conclusions: Our study indicates that low expression of H3K27me3 might be considered as a predictor for poor prognosis and recurrence, and it may provide a potential therapeutic target for conventional chordoma patients.


  • Cutaneous melanocytic tumour with CRTC1::TRIM11 fusion in a case with recurrent local lymph node and distant pulmonary metastases at early stage: aggressive rather than indolent?

    by Li Yang, Zhiyong Yin, Jie Wei, Jia Chai, Danhui Zhao, Yixiong Liu, Yongqiang Tang, Hong Cheng, Wang Zhe, Linni Fan


  • Circulating tumor DNA targeted sequencing predicts the prognosis of mCRPC patients

    by B. Dong, L. Fan, B. Yang, K. Wu, F. Zhang, W. Chen, C. Huihua, J. Pan, Y. Zhu, C. Luo, et al.